A Phase 3 interventional study of TDV and Placebo in Healthy Volunteers, sponsored by Takeda. Completed at 10 sites in India. Open to participants aged 4 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Takeda · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main aims of the study are to learn about side effects and a participant's immune response to Takeda's Dengue Vaccine when given twice within 3 months.
Participants will receive 2 doses of their randomized treatment (vaccine or placebo). Children, teenagers and adults will receive one dose of either the vaccine or placebo on Day 1 and the second dose of either the vaccine or placebo 3 months later. Up to 4 blood samples will be taken throughout the study.
During the study, participants will visit their study clinic 6 times.
The vaccine being tested in this study is called TDV (Live, Attenuated). TDV is being tested to prevent dengue. This study will assess the safety and immunogenicity of TDV in healthy participants.
The study will enroll approximately 480 patients. Participants will be randomly assigned (by chance, like flipping a coin) to receive either TDV or placebo- which will remain undisclosed to the participant, and investigator during the study:
This multi-center trial will be conducted in India. The overall duration of the study is approximately 9 months.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
1. Participants who can comply with trial procedures and are available for the duration of follow-up.
Key Exclusion Criteria:
At screening and at vaccination:
Plans to receive any of the following:
At Vaccination:
NOTE: Other protocol defined Inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received TDV subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) of the study.
Biological: TDV
Participants received TDV-matching placebo SC injection on Day 1 (Month 0) and Day 90 (Month 3) of the study.
Biological: Placebo
Participants received TDV SC injection on Day 1 (Month 0) and Day 90 (Month 3) of the study.
Biological: TDV
Participants received TDV-matching placebo SC injection on Day 1 (Month 0) and Day 90 (Month 3) of the study.
Biological: Placebo
TDV SC injection on Day 1 and Day 90 of the study
Also known as: TAK-003
Normal Saline (0.9% NaCl) SC injection on Day 1 and Day 90 of the study
Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity Within 7 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years
Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for infant/toddler/child (\<6 years of age).
Time frame: Within 7 days post-vaccination at Day 1
Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 1 for Age Group 6 Years and Over
Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for child/adolescent/adult (≥6 years of age).
Time frame: Within 7 days post-vaccination at Day 1
Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years
Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for infant/toddler/child (\<6 years of age).
Time frame: Within 7 days post-vaccination at Day 90
Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 90 for Age Group 6 Years and Over
Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for child/adolescent/adult (≥6 years of age).
Time frame: Within 7 days post-vaccination at Day 90
Number of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children \<6 years old comprised: irritability/fussiness, drowsiness, loss of appetite (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe) and fever in °C (collected by temperature ranges as indicated).
Time frame: Within 14 days post-vaccination at Day 1
Number of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 1 for Age Group 6 Years and Over
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children ≥ 6 years old/adolescents/adults comprised: headache, asthenia, malaise, myalgia (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe) and fever in °C (collected by temperature ranges as indicated).
Time frame: Within 14 days post-vaccination at Day 1
Number of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children \<6 years old comprised: drowsiness, irritability/fussiness, loss of appetite (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe). Data for drowsiness, irritability/fussiness and loss of appetite has been reported in this outcome measure.
Time frame: Within 14 days post-vaccination at Day 90
Number of Participants With Solicited Systemic AEs of Fever by Severity Within 14 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children \<6 years old also comprised of fever in °C (collected by temperature ranges as indicated). Data for fever has been reported in this outcome measure.
Time frame: Within 14 days post-vaccination at Day 90
Number of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 90 for Age Group 6 Years and Over
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children ≥ 6 years old/adolescents/adults comprised: headache, asthenia, malaise, myalgia (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe) and fever in °C (collected by temperature ranges as indicated).
Time frame: Within 14 days post-vaccination at Day 90
Percentage of Participants With Any Unsolicited AEs Within 28 Days Post-vaccination at Day 1
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
Time frame: Within 28 days post-vaccination at Day 1
Percentage of Participants With Any Unsolicited AEs Within 28 Days Post-vaccination at Day 90
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
Time frame: Within 28 days post-vaccination at Day 90
Percentage of Participants With an AE Leading to Participant Withdrawal From Trial
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
Time frame: From first vaccination on Day 1 through the end of trial (up to Day 270)
Percentage of Participants With an AE Leading to TDV or Placebo Discontinuation
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
Time frame: From first vaccination on Day 1 through the end of trial (up to Day 270)
Percentage of Participants With a Medically-attended AE (MAAE)
MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department but not fulfilling seriousness criteria.
Time frame: From first vaccination on Day 1 through the end of trial (up to Day 270)
Percentage of Participants With a Serious Adverse Event (SAE)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event.
Time frame: From first vaccination on Day 1 through the end of trial (up to Day 270)
GMTs of Neutralizing Antibodies by Microneutralization Test (MNT50) for Each of the 4 Dengue Virus Serotypes at Day 120
GMTs of neutralizing antibodies were measured by microneutralization test 50% (MNT50) for each of the 4 dengue serotypes for all participants. The 4 dengue virus serotypes (DENV) are DENV-1, DENV-2, DENV-3 and DENV-4.
Time frame: Day 120 (Month 4)
GMTs by MNT50 Against Each of the 4 Dengue Virus Serotypes at Day 1 and Day 270
GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 dengue serotypes for all participants. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.
Time frame: Day 1 and 270
Percentage of Participants With Seroconversion for Each of the 4 Dengue Virus Serotypes
Seroconversion rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositive is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.
Time frame: Day 1, Day 120 and Day 270
Percentage of Participants With Seroconversion for Multiple (2, 3, or 4) Dengue Virus Serotypes
Seroconversion rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositive is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.
Time frame: Day 1, Day 120 and Day 270
Participants took part in the study at 10 investigative sites in India from 29 March 2024 to 05 May 2025.
| Milestone | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Years Age Group: TDV | Cohort 2: ≥4 to <18 Years Age Group: Placebo |
|---|---|---|---|---|
| Started | 180 | 60 | 180 | 60 |
| Completed | 175 | 59 | 178 | 58 |
| Not completed | 5 | 1 | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 1 |
| Withdrew: Reason not specified | 1 | 0 | 1 | 0 |
Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for infant/toddler/child (\<6 years of age).
| Participants | Cohort 2: ≥4 to <6 Years Age Group: TDV | Cohort 2: ≥4 to <6 Years Age Group: Placebo |
|---|---|---|
| Pain: None | 42 | 10 |
| Pain: Mild | 4 | 4 |
| Pain: Moderate | 0 | 0 |
| Pain: Severe | 0 | 0 |
| Erythema: None | 46 | 14 |
| Erythema: Mild | 0 | 0 |
| Erythema: Moderate | 0 | 0 |
| Erythema: Severe | 0 | 0 |
| Swelling: None | 45 | 14 |
| Swelling: Mild | 1 | 0 |
| Swelling: Moderate | 0 | 0 |
| Swelling: Severe | 0 | 0 |
Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for child/adolescent/adult (≥6 years of age).
| Participants | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥6 to <18 Years Age Group: TDV | Cohort 2: ≥6 to <18 Years Age Group: Placebo |
|---|---|---|---|---|
| Pain: None | 152 | 53 | 119 | 42 |
| Pain: Mild | 25 | 7 | 13 | 4 |
| Pain: Moderate | 2 | 0 | 1 | 0 |
| Pain: Severe | 0 | 0 | 0 | 0 |
| Erythema: None | 177 | 60 | 133 | 46 |
| Erythema: Mild | 2 | 0 | 0 | 0 |
| Erythema: Moderate | 0 | 0 | 0 | 0 |
| Erythema: Severe | 0 | 0 | 0 | 0 |
| Swelling: None | 179 | 60 | 132 | 46 |
| Swelling: Mild | 0 | 0 | 1 | 0 |
| Swelling: Moderate | 0 | 0 | 0 | 0 |
| Swelling: Severe | 0 | 0 | 0 | 0 |
Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for infant/toddler/child (\<6 years of age).
| Participants | Cohort 2: ≥4 to <6 Years Age Group: TDV | Cohort 2: ≥4 to <6 Years Age Group: Placebo |
|---|---|---|
| Pain: None | 44 | 14 |
| Pain: Mild | 2 | 0 |
| Pain: Moderate | 0 | 0 |
| Pain: Severe | 0 | 0 |
| Erythema: None | 46 | 14 |
| Erythema: Mild | 0 | 0 |
| Erythema: Moderate | 0 | 0 |
| Erythema: Severe | 0 | 0 |
| Swelling: None | 46 | 14 |
| Swelling: Mild | 0 | 0 |
| Swelling: Moderate | 0 | 0 |
| Swelling: Severe | 0 | 0 |
Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for child/adolescent/adult (≥6 years of age).
| Participants | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥6 to <18 Years Age Group: TDV | Cohort 2: ≥6 to <18 Years Age Group: Placebo |
|---|---|---|---|---|
| Pain: None | 163 | 55 | 117 | 41 |
| Pain: Mild | 12 | 3 | 14 | 4 |
| Pain: Moderate | 1 | 1 | 1 | 0 |
| Pain: Severe | 0 | 0 | 0 | 0 |
| Erythema: None | 176 | 59 | 132 | 45 |
| Erythema: Mild | 0 | 0 | 0 | 0 |
| Erythema: Moderate | 0 | 0 | 0 | 0 |
| Erythema: Severe | 0 | 0 | 0 | 0 |
| Swelling: None | 176 | 59 | 132 | 45 |
| Swelling: Mild | 0 | 0 | 0 | 0 |
| Swelling: Moderate | 0 | 0 | 0 | 0 |
| Swelling: Severe | 0 | 0 | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children \<6 years old comprised: irritability/fussiness, drowsiness, loss of appetite (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe) and fever in °C (collected by temperature ranges as indicated).
| Participants | Cohort 2: ≥4 to <6 Years Age Group: TDV | Cohort 2: ≥4 to <6 Years Age Group: Placebo |
|---|---|---|
| Irritability or Fussiness: None | 45 | 13 |
| Irritability or Fussiness: Mild | 1 | 1 |
| Irritability or Fussiness: Moderate | 0 | 0 |
| Irritability or Fussiness: Severe | 0 | 0 |
| Drowsiness: None | 45 | 13 |
| Drowsiness: Mild | 1 | 1 |
| Drowsiness: Moderate | 0 | 0 |
| Drowsiness: Severe | 0 | 0 |
| Loss of Appetite: None | 46 | 14 |
| Loss of Appetite: Mild | 0 | 0 |
| Loss of Appetite: Moderate | 0 | 0 |
| Loss of Appetite: Severe | 0 | 0 |
| Fever: None | 46 | 14 |
| Fever: 38.0-<38.5 °C | 0 | 0 |
| Fever: 38.5-<39.0 °C | 0 | 0 |
| Fever: 39.0-<39.5 °C | 0 | 0 |
| Fever: 39.5-<40.0 °C | 0 | 0 |
| Fever: 40.0-<40.5 °C | 0 | 0 |
| Fever: 40.5-<41.0 °C | 0 | 0 |
| Fever: ≥41.0 °C | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children ≥ 6 years old/adolescents/adults comprised: headache, asthenia, malaise, myalgia (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe) and fever in °C (collected by temperature ranges as indicated).
| Participants | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥6 to <18 Years Age Group: TDV | Cohort 2: ≥6 to <18 Years Age Group: Placebo |
|---|---|---|---|---|
| Headache: None | 165 | 54 | 127 | 45 |
| Headache: Mild | 11 | 6 | 6 | 1 |
| Headache: Moderate | 1 | 0 | 0 | 0 |
| Headache: Severe | 2 | 0 | 0 | 0 |
| Asthenia: None | 168 | 56 | 126 | 44 |
| Asthenia: Mild | 11 | 4 | 6 | 2 |
| Asthenia: Moderate | 0 | 0 | 1 | 0 |
| Asthenia: Severe | 0 | 0 | 0 | 0 |
| Malaise: None | 174 | 57 | 130 | 46 |
| Malaise: Mild | 5 | 3 | 2 | 0 |
| Malaise: Moderate | 0 | 0 | 1 | 0 |
| Malaise: Severe | 0 | 0 | 0 | 0 |
| Myalgia: None | 168 | 56 | 128 | 45 |
| Myalgia: Mild | 10 | 3 | 4 | 1 |
| Myalgia: Moderate | 1 | 1 | 1 | 0 |
| Myalgia: Severe | 0 | 0 | 0 | 0 |
| Fever: None | 178 | 58 | 131 | 45 |
| Fever: 38.0-<38.5 °C | 0 | 2 | 1 | 0 |
| Fever: 38.5-<39.0 °C | 0 | 0 | 0 | 0 |
| Fever: 39.0-<39.5 °C | 0 | 0 | 0 | 1 |
| Fever: 39.5-<40.0 °C | 0 | 0 | 0 | 0 |
| Fever: 40.0-<40.5 °C | 1 | 0 | 1 | 0 |
| Fever: 40.5-<41.0 °C | 0 | 0 | 0 | 0 |
| Fever: ≥41.0 °C | 0 | 0 | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children \<6 years old comprised: drowsiness, irritability/fussiness, loss of appetite (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe). Data for drowsiness, irritability/fussiness and loss of appetite has been reported in this outcome measure.
| Participants | Cohort 2: ≥4 to <6 Years Age Group: TDV | Cohort 2: ≥4 to <6 Years Age Group: Placebo |
|---|---|---|
| Irritability or Fussiness: None | 38 | 14 |
| Irritability or Fussiness: Mild | 0 | 0 |
| Irritability or Fussiness: Moderate | 0 | 0 |
| Irritability or Fussiness: Severe | 0 | 0 |
| Drowsiness: None | 37 | 13 |
| Drowsiness: Mild | 1 | 1 |
| Drowsiness: Moderate | 0 | 0 |
| Drowsiness: Severe | 0 | 0 |
| Loss of Appetite: None | 38 | 13 |
| Loss of Appetite: Mild | 0 | 1 |
| Loss of Appetite: Moderate | 0 | 0 |
| Loss of Appetite: Severe | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children \<6 years old also comprised of fever in °C (collected by temperature ranges as indicated). Data for fever has been reported in this outcome measure.
| Participants | Cohort 2: ≥4 to <6 Years Age Group: TDV | Cohort 2: ≥4 to <6 Years Age Group: Placebo |
|---|---|---|
| Fever: None | 46 | 14 |
| Fever: 38.0-<38.5 °C | 0 | 0 |
| Fever: 38.5-<39.0 °C | 0 | 0 |
| Fever: 39.0-<39.5 °C | 0 | 0 |
| Fever: 39.5-<40.0 °C | 0 | 0 |
| Fever: 40.0-<40.5 °C | 0 | 0 |
| Fever: 40.5-<41.0 °C | 0 | 0 |
| Fever: ≥41.0 °C | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children ≥ 6 years old/adolescents/adults comprised: headache, asthenia, malaise, myalgia (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe) and fever in °C (collected by temperature ranges as indicated).
| Participants | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥6 to <18 Years Age Group: TDV | Cohort 2: ≥6 to <18 Years Age Group: Placebo |
|---|---|---|---|---|
| Headache: None | 169 | 59 | 129 | 45 |
| Headache: Mild | 6 | 0 | 3 | 0 |
| Headache: Moderate | 1 | 0 | 0 | 0 |
| Headache: Severe | 0 | 0 | 0 | 0 |
| Asthenia: None | 172 | 58 | 129 | 44 |
| Asthenia: Mild | 3 | 1 | 3 | 1 |
| Asthenia: Moderate | 1 | 0 | 0 | 0 |
| Asthenia: Severe | 0 | 0 | 0 | 0 |
| Malaise: None | 173 | 59 | 132 | 45 |
| Malaise: Mild | 3 | 0 | 0 | 0 |
| Malaise: Moderate | 0 | 0 | 0 | 0 |
| Malaise: Severe | 0 | 0 | 0 | 0 |
| Myalgia: None | 173 | 59 | 129 | 44 |
| Myalgia: Mild | 1 | 0 | 3 | 1 |
| Myalgia: Moderate | 2 | 0 | 0 | 0 |
| Myalgia: Severe | 0 | 0 | 0 | 0 |
| Fever: None | 172 | 57 | 129 | 44 |
| Fever: 38.0-<38.5 °C | 3 | 1 | 2 | 0 |
| Fever: 38.5-<39.0 °C | 1 | 1 | 0 | 1 |
| Fever: 39.0-<39.5 °C | 0 | 0 | 0 | 0 |
| Fever: 39.5-<40.0 °C | 0 | 0 | 0 | 0 |
| Fever: 40.0-<40.5 °C | 0 | 0 | 1 | 0 |
| Fever: 40.5-<41.0 °C | 0 | 0 | 0 | 0 |
| Fever: ≥41.0 °C | 0 | 0 | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
| percentage of participants | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Age Group: TDV | Cohort 2: ≥4 to <18 Age Group: Placebo |
|---|---|---|---|---|
| Percentage of Participants With Any Unsolicited AEs Within 28 Days Post-vaccination at Day 1 | 2.2 | 1.7 | 2.2 | 1.7 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
| percentage of participants | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Age Group: TDV | Cohort 2: ≥4 to <18 Age Group: Placebo |
|---|---|---|---|---|
| Percentage of Participants With Any Unsolicited AEs Within 28 Days Post-vaccination at Day 90 | 1.7 | 3.4 | 4.5 | 3.4 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
| percentage of participants | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Age Group: TDV | Cohort 2: ≥4 to <18 Age Group: Placebo |
|---|---|---|---|---|
| Percentage of Participants With an AE Leading to Participant Withdrawal From Trial | 0.6 | 0 | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
| percentage of participants | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Age Group: TDV | Cohort 2: ≥4 to <18 Age Group: Placebo |
|---|---|---|---|---|
| Percentage of Participants With an AE Leading to TDV or Placebo Discontinuation | 0.6 | 0 | 0 | 0 |
MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department but not fulfilling seriousness criteria.
| percentage of participants | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Age Group: TDV | Cohort 2: ≥4 to <18 Age Group: Placebo |
|---|---|---|---|---|
| Percentage of Participants With a Medically-attended AE (MAAE) | 5.0 | 3.3 | 10.0 | 13.3 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event.
| percentage of participants | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Years Age Group: TDV | Cohort 2: ≥4 to <18 Years Age Group: Placebo |
|---|---|---|---|---|
| Percentage of Participants With a Serious Adverse Event (SAE) | 0.0 | 0.0 | 0.0 | 0.0 |
GMTs of neutralizing antibodies were measured by microneutralization test 50% (MNT50) for each of the 4 dengue serotypes for all participants. The 4 dengue virus serotypes (DENV) are DENV-1, DENV-2, DENV-3 and DENV-4.
| titers | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Age Group: TDV | Cohort 2: ≥4 to <18 Age Group: Placebo |
|---|---|---|---|---|
| DENV-1 | 3196.9 ± 5.36 | 676.6 ± 13.70 | 2968.0 ± 4.50 | 267.9 ± 14.31 |
| DENV-2 | 2547.3 ± 4.34 | 624.2 ± 12.63 | 2869.1 ± 3.78 | 316.6 ± 15.66 |
| DENV-3 | 1616.0 ± 5.13 | 452.3 ± 10.42 | 1596.7 ± 4.82 | 196.8 ± 14.67 |
| DENV-4 | 999.0 ± 4.65 | 265.9 ± 8.42 | 1018.4 ± 4.15 | 135.8 ± 10.97 |
GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 dengue serotypes for all participants. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.
| titers | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Age Group: TDV | Cohort 2: ≥4 to <18 Age Group: Placebo |
|---|---|---|---|---|
| Day 1: DENV-1 | 1038.5 ± 10.63 | 699.8 ± 12.42 | 362.0 ± 14.27 | 223.1 ± 16.76 |
| Day 1: DENV-2 | 797.9 ± 9.95 | 460.1 ± 13.63 | 418.4 ± 12.92 | 314.1 ± 19.00 |
| Day 1: DENV-3 | 618.9 ± 9.23 | 463.9 ± 10.91 | 238.2 ± 11.60 | 202.4 ± 17.11 |
| Day 1: DENV-4 | 392.4 ± 8.61 | 275.3 ± 10.61 | 166.8 ± 10.05 | 147.3 ± 17.29 |
| Day 270: DENV-1 | 2557.9 ± 4.80 | 703.3 ± 10.97 | 1531.5 ± 6.27 | 393.9 ± 12.85 |
| Day 270: DENV-2 | 2454.6 ± 3.69 | 548.9 ± 12.17 | 1740.7 ± 5.61 | 441.7 ± 16.56 |
| Day 270: DENV-3 | 1067.8 ± 5.19 | 402.9 ± 10.99 | 765.2 ± 7.63 | 287.8 ± 13.11 |
| Day 270: DENV-4 | 708.7 ± 4.94 | 188.9 ± 9.79 | 452.0 ± 6.61 | 172.6 ± 11.28 |
Seroconversion rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositive is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.
| percentage of participants | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Age Group: TDV | Cohort 2: ≥4 to <18 Age Group: Placebo |
|---|---|---|---|---|
| Day 1: DENV-1 | 90.9 | 86.4 | 82.6 | 76.3 |
| Day 1: DENV-2 | 91.5 | 83.1 | 87.1 | 83.1 |
| Day 1: DENV-3 | 88.6 | 86.4 | 79.2 | 72.9 |
| Day 1: DENV-4 | 85.8 | 79.7 | 78.1 | 69.5 |
| Day 120: DENV-1 | 98.3 | 83.1 | 100 | 83.1 |
| Day 120: DENV-2 | 98.3 | 86.4 | 100 | 78.0 |
| Day 120: DENV-3 | 98.9 | 86.4 | 100 | 71.2 |
| Day 120: DENV-4 | 97.7 | 84.7 | 100 | 72.9 |
| Day 270: DENV-1 | 98.9 | 89.8 | 99.4 | 86.2 |
| Day 270: DENV-2 | 99.4 | 89.8 | 98.3 | 81.0 |
| Day 270: DENV-3 | 98.3 | 83.1 | 96.6 | 81.0 |
| Day 270: DENV-4 | 95.4 | 78.0 | 92.7 | 75.9 |
Seroconversion rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositive is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.
| percentage of participants | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Age Group: TDV | Cohort 2: ≥4 to <18 Age Group: Placebo |
|---|---|---|---|---|
| Day 1: Monovalent | 5.7 | 5.1 | 8.4 | 8.5 |
| Day 1: Bivalent | 2.3 | 1.7 | 4.5 | 5.1 |
| Day 1: Trivalent | 1.1 | 5.1 | 0.6 | 1.7 |
| Day 1: Tetravalent | 85.8 | 78.0 | 77.0 | 69.5 |
| Day 120: Monovalent | 0.0 | 1.7 | 0.0 | 13.6 |
| Day 120: Bivalent | 0.6 | 3.4 | 0.0 | 3.4 |
| Day 120: Trivalent | 1.1 | 0.0 | 0.6 | 0 |
| Day 120: Tetravalent | 97.2 | 83.1 | 99.4 | 71.2 |
| Day 270: Monovalent | 0.6 | 13.6 | 0.6 | 10.3 |
| Day 270: Bivalent | 0.6 | 0.0 | 1.7 | 5.2 |
| Day 270: Trivalent | 4.0 | 5.1 | 5.6 | 0 |
| Day 270: Tetravalent | 94.3 | 78.0 | 91.6 | 75.9 |
Collected over All cause mortality and SAE: From Day 1 through end of trial on Day 270; Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) following administration of TDV or placebo. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: >=18 to <=60 Age Group: TDV | 0/180 (0%) | 0/180 (0%) | 53/180 (29.4%) |
| Cohort 1: >=18 to <=60 Age Group: Placebo | 0/60 (0%) | 0/60 (0%) | 19/60 (31.7%) |
| Cohort 2: >=4 to <18 Age Group: TDV | 0/180 (0%) | 0/180 (0%) | 52/180 (28.9%) |
| Cohort 2: >=4 to <18 Age Group: Placebo | 0/60 (0%) | 0/60 (0%) | 15/60 (25%) |
| Event | Cohort 1: >=18 to <=60 Age Group: TDV | Cohort 1: >=18 to <=60 Age Group: Placebo | Cohort 2: >=4 to <18 Age Group: TDV | Cohort 2: >=4 to <18 Age Group: Placebo |
|---|---|---|---|---|
| PainGeneral disorders | 38/180 | 8/60 | 41/180 | 15/60 |
| HeadacheNervous system disorders | 20/180 | 7/60 | 8/180 | 1/60 |
| AstheniaGeneral disorders | 15/180 | 5/60 | 10/180 | 3/60 |
| MyalgiaMusculoskeletal and connective tissue disorders | 14/180 | 4/60 | 7/180 | 2/60 |
| Body temperatureInvestigations | 5/180 | 4/60 | 5/180 | 1/60 |
Randomized Set included all randomized participants, regardless of whether any dose of the investigational product (IP) was received.
| Age, Continuous(years) | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Years Age Group: TDV | Cohort 2: ≥4 to <18 Years Age Group: Placebo | Total |
|---|---|---|---|---|---|
| Mean | 37.2 ± 11.66 | 36.5 ± 11.12 | 9.7 ± 4.05 | 10.3 ± 4.35 | 23.4 ± 16.12 |
| Sex: Female, Male(Participants) | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Years Age Group: TDV | Cohort 2: ≥4 to <18 Years Age Group: Placebo | Total |
|---|---|---|---|---|---|
| Female | 54 | 14 | 79 | 29 | 176 |
| Male | 126 | 46 | 101 | 31 | 304 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Years Age Group: TDV | Cohort 2: ≥4 to <18 Years Age Group: Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 180 | 60 | 180 | 59 | 479 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Cohort 1: ≥18 to ≤60 Years Age Group: TDV | Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | Cohort 2: ≥4 to <18 Years Age Group: TDV | Cohort 2: ≥4 to <18 Years Age Group: Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 180 | 60 | 180 | 59 | 479 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2024 to primary completion in May 2025, 13 months.
Results were first posted in May 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.